VICP Vicapsys Life Sciences, Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1468639 · Fiscal year ends 12/31
Financial factors as of 2024-09-30 (2024Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-24.8%
TTM EPS YoY0.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-904.2%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets3,053.8%
Debt / equity—
Current ratio0.03x
Interest coverage-62.88x
Cash quality & payout
Operating cash flow / net income0.09x
Accruals ratio-819.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 | FY20202020-12-31 | FY20192019-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $15,267 | $13,097 | $17,698 | $102,180 | $98,983 |
| SG&A expense | $96,431 | $60,198 | $35,790 | $46,957 | $54,111 |
| Operating income | -$1.05M | -$984,790 | -$336,871 | -$765,844 | — |
| Interest expense | $19,969 | — | — | — | — |
| Pretax income | -$1.18M | -$984,790 | -$236,871 | -$765,844 | -$1.03M |
| Net income | -$1.18M | -$984,790 | -$236,871 | -$765,844 | -$1.41M |
| EPS (basic) | -0.03 | -0.03 | -0.01 | -0.04 | -0.13 |
| EPS (diluted) | -0.03 | -0.03 | -0.01 | -0.04 | -0.13 |
| Weighted avg. shares (diluted) | 34.55M | 30.58M | 17.66M | 17.48M | 11.40M |
| Balance sheet | |||||
| Cash & equivalents | $9,422 | $14,097 | $217,295 | $1,269 | $264,166 |
| Current assets | $39,656 | $72,021 | $222,793 | $1,269 | $264,166 |
| Intangibles | — | — | $371,520 | $402,849 | $434,273 |
| Total assets | $39,656 | $72,021 | $594,313 | $404,118 | $698,439 |
| Current liabilities | $1.97M | $1.02M | $715,964 | $853,224 | $396,482 |
| Short-term debt | $18,712 | — | — | — | — |
| Total liabilities | $1.97M | $1.02M | $715,964 | $853,224 | $396,482 |
| Shareholders' equity | -$1.93M | -$950,791 | -$121,651 | -$449,106 | $301,957 |
| Shares outstanding | 32.07M | 31.19M | 19.75M | 17.48M | 17.48M |
| Cash flow statement | |||||
| Operating cash flow | -$417,524 | -$238,197 | -$443,974 | -$262,897 | -$970,264 |
| Investing cash flow | — | — | $100,000 | — | — |
| Financing cash flow | $412,849 | $34,999 | $560,000 | — | $1.15M |
| Depreciation & amortization | — | — | — | — | $30,364 |
| Stock-based compensation | $20,697 | $105,650 | $4,326 | $14,781 | $118,649 |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.